Show simple item record

dc.contributor.authorDearnaley, DPen_US
dc.contributor.authorSaltzstein, DRen_US
dc.contributor.authorSylvester, JEen_US
dc.contributor.authorKarsh, Len_US
dc.contributor.authorMehlhaff, BAen_US
dc.contributor.authorPieczonka, Cen_US
dc.contributor.authorBailen, JLen_US
dc.contributor.authorShi, Hen_US
dc.contributor.authorYe, Zen_US
dc.contributor.authorFaessel, HMen_US
dc.contributor.authorLin, Hen_US
dc.contributor.authorZhu, Yen_US
dc.contributor.authorSaad, Fen_US
dc.contributor.authorMacLean, DBen_US
dc.contributor.authorShore, NDen_US
dc.date.accessioned2020-05-22T15:11:45Z
dc.date.issued2020-08en_US
dc.identifier.citationEuropean urology, 2020, 78 (2), pp. 184 - 192en_US
dc.identifier.issn0302-2838en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3629
dc.identifier.eissn1873-7560en_US
dc.identifier.doi10.1016/j.eururo.2020.03.001en_US
dc.description.abstractBACKGROUND:External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT) is an established treatment option to prolong survival for patients with intermediate- and high-risk prostate cancer (PCa). Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, was evaluated in this clinical setting in comparison with degarelix, an injectable GnRH antagonist. OBJECTIVE:To evaluate the safety and efficacy of relugolix to achieve and maintain castration. DESIGN, SETTING, AND PARTICIPANTS:A phase 2 open-label study was conducted in 103 intermediate-risk PCa patients undergoing primary EBRT and neoadjuvant/adjuvant ADT between June 2014 and December 2015. INTERVENTION:Patients randomly assigned (3:2) to 24-wk treatment with either daily oral relugolix or 4-wk subcutaneous depot degarelix (reference control). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:The primary endpoint was the rate of effective castration (testosterone <1.73nmol/l) in relugolix patients between 4 and 24 wk of treatment. Secondary endpoints included rate of profound castration (testosterone <0.7nmol/l), prostate-specific antigen (PSA) levels, prostate volume, quality of life (QoL) assessed using the Aging Males' Symptoms scale, and the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (30-item EORTC core questionnaire [EORTC QLQ-C30] and 25-item EORTC prostate cancer module [EORTC QLQ-PR25]) questionnaires, and safety. No formal statistical comparisons with degarelix were planned. RESULTS AND LIMITATIONS:Castration rates during treatment were 95% and 82% with relugolix and 89% and 68% with degarelix for 1.73 and 0.7nmol/l thresholds, respectively. Median time to castration in the relugolix arm was 4 d. During treatment, PSA levels and prostate volumes were reduced in both groups. Three months after discontinuing treatment, 52% of men on relugolix and 16% on degarelix experienced testosterone recovery (statistical significance of differences not tested). Mean and median QoL scores improved following treatment discontinuation. The most common adverse event was hot flush (relugolix 57%; degarelix 61%). Lack of blinding was a potential limitation. CONCLUSIONS:Relugolix achieved testosterone suppression to castrate levels within days and maintained it over 24 wk with a safety profile consistent with its mechanism of action. PATIENT SUMMARY:Oral once-daily relugolix may be a novel oral alternative to injectable androgen deprivation therapies.en_US
dc.formatPrint-Electronicen_US
dc.format.extent184 - 192en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleThe Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.en_US
dc.typeJournal Article
dcterms.dateAccepted2020-03-02en_US
rioxxterms.versionofrecord10.1016/j.eururo.2020.03.001en_US
rioxxterms.licenseref.startdate2020-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEuropean urologyen_US
pubs.issue2en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Dearnaley)
pubs.publication-statusPublisheden_US
pubs.volume78en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Academic Radiotherapy (Dearnaley)en_US
dc.contributor.icrauthorDearnaley, Daviden_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/